IL2 and neoplasm: IL-2 with abrogated IL-2Rα (CD25) binding or enhanced IL-2Rβ binding was demonstrated to induce less efficient Treg expansion and tumor infiltration, with more efficient tumor-specific CD8+ T-cell proliferation [47,61].